Rimonabant-induced catatonia in schizophrenia: A case report

Reddy, Nalini N. ; Rao, Naren P. ; Venkatasubramanian, Ganesan ; Arasappa, Rashmi ; Behere, Rishikesh V. ; Divakaran, Anjith ; Sivakumar, Palanimuthu T. ; Gangadhar, Bangalore N. (2009) Rimonabant-induced catatonia in schizophrenia: A case report Obesity Research & Clinical Practice, 3 (4). pp. 237-239. ISSN 1871-403X

Full text not available from this repository.

Official URL: http://doi.org/10.1016/j.orcp.2009.04.002

Related URL: http://dx.doi.org/10.1016/j.orcp.2009.04.002


Patients with psychiatric illness have higher rates of mortality and medical co-morbidity related to increased rates of diabetes mellitus and cardiovascular disease. Rimonabant, a cannabinoid receptor (CB1) antagonist, is an anti-obesity agent and decreases risk for metabolic syndrome. Though there are reports of rimonabant associated with adverse psychiatric events like depression, rimonabant-induced catatonia is not reported. In this first time report, we describe a patient with schizophrenia developing catatonia possibly due to rimonabant.

Item Type:Article
Source:Copyright of this article belongs to Elsevier B.V..
Keywords:Schizophrenia; Catatonia; Rimonabant; Metabolic Syndrome; Obesity.
ID Code:119089
Deposited On:08 Jun 2021 05:08
Last Modified:08 Jun 2021 05:08

Repository Staff Only: item control page